These studies have shown the potential role of AFP and ICAM-1 in tumor immunomodulation, but they have not conducted multifaceted assessments to determine whether AFP and ICAM-1 can be potential targets for HCC immunotherapy. Here, ICAM1 is linked to neoplasm.